22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On September 24, 2019, the U.S. Department of Labor (DOL) announced a final rule to make an estimate...
Read More >
Over the past few years, Germany has strengthened the AWV regime. In parallel, the relevance of Germ...
Read More >
Tell us about your practice in the middle-market private equity space? I represent private equity ...
Read More >
Rep and Warranty Insurance (RWI) generally provides coverage for financial losses resulting from bre...
Read More >
Colleges and universities have witnessed major developments in September with student teaching and r...
Read More >
President Trump continues to push forward with his “Buy American, Hire American” initiative with t...
Read More >